Heading 2



Alibion was born to bring new drug discoveries out of academic labs and closer to patients. We accelerate the development of therapeutics through early stages. Our efforts are focused on identifying promising novel therapeutics and pooling the necessary resources to drive these compounds out of the labs and into late-stage development. We strive to improve patient outcomes worldwide by bringing innovative therapeutics closer to patients. Join us and together lets build a better, healthier future.

We are currently developing ALB001, the first personalized medicine against Rheumatoid arthritis. 

Thanks to the generous support of: 



Together to advance new therapies closer to patients


Our Vision

We will become leaders in the early-stage development of therapeutics. We will achieve continuity and growth with a replicable, standardized process.


Alibion AG

c/o Switzerland Innovation Park Basel Area AG
Gewerbestrasse 24, 4123 Allschwil


Tel: +41 79 549 0242

For enquiries, leave us a message below

Please note: We are not currently looking for graphic designers, etc. Emails from Alibion will always end on:  "@alibion.com"


© Alibion AG 2018